Providing consultancy and research in health economics for the NHS, pharmaceutical and health care industries since 1986 WHITEWATER CHARITABLE TRUST The Cost of Sepsis Care in the UK Final Report NICK HEX, Associate Director JENNY RETZLER, Research Consultant CHRIS BARTLETT, Research Consultant MICK ARBER, Senior Information Specialist 17 February 2017
46
Embed
The Cost of Sepsis Care in the UK Final Report€¦ · 2.1 Methodological Approach and Limitations 5 2.2 Literature Search Methodology 5 2.3 Literature Search Results 7 2.4 Cost Modelling
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Providing consultancy and research in health economics for the
NHS, pharmaceutical and health care industries since 1986
WHITEWATER CHARITABLE TRUST
The Cost of Sepsis Care in the UK
Final Report
NICK HEX, Associate Director
JENNY RETZLER, Research Consultant
CHRIS BARTLETT, Research Consultant
MICK ARBER, Senior Information Specialist
17 February 2017
All reasonable precautions have been taken by YHEC to verify the information
contained in this publication. However, the published material is being distributed
without warranty of any kind, either expressed or implied. The responsibility for the
interpretation and use of the material lies with the reader. In no event shall YHEC be
liable for damages arising from its use.
Contents
Page No.
Executive Summary
Acknowledgements
Section 1: Introduction 1
1.1 Background to Sepsis 1
1.2 NICE Guideline on Sepsis 2
1.3 Study Objectives 3
Section 2: Methodology 5
2.1 Methodological Approach and Limitations 5
2.2 Literature Search Methodology 5
2.3 Literature Search Results 7
2.4 Cost Modelling Approach 8
Section 3: Estimated Costs 10
3.1 Model Inputs 10
3.2 Incidence and Prevalence Estimates and Mortality Data 11
3.3 Direct Cost Estimates 12
3.4 Indirect Cost Estimates 16
3.5 Potential Impact of Improvements in Care for Sepsis 18
3.6 Scenario Analysis 19
Section 4: Discussion 21
4.1 Summary 21
4.2 Study Limitations 21
4.3 Conclusions 23
4.4 Recommendations 23
References
Appendices:
Appendix A: Search Strategy for Ovid MEDLINE
Appendix B: Narrative Synthesis of Eligible Studies in the Burden of Illness Review
Appendix C: Results of Pragmatic Searches
i
Executive Summary
1. INTRODUCTION
The aim of this report is to highlight the considerable costs associated with sepsis in the UK.
Sepsis is a potentially life-threatening condition caused by infection from numerous potential
sources. In more severe forms it results in hospital admission and the most severe forms
require treatment in intensive care. There is a high mortality rate associated with patients
with sepsis. This implies significant costs to both the health care system and society more
broadly.
Despite the economic and human costs associated with sepsis there are very little data on
incidence, care pathways and costs in the UK. The incidence of sepsis may be under-
reported as sepsis may be attributed to other conditions such as pneumonia. There is
consensus that much more could be done to recognise sepsis at an earlier stage in many
cases, and that if this were the case, deaths, complications and the use of hospital
resources could be reduced.
In 2016, the National Institute for Health and Care Excellence (NICE) published a guideline
which included interventions which aimed to improve diagnosis and management of sepsis.
The Guideline Development Group identified that records of prevalence and incidence of
sepsis in the UK are not robust and did not carry out cost-effectiveness modelling.
This study has attempted to gather the data and evidence on the cost burden of sepsis that
do exist and to use them to develop some estimates of the potential range of the current cost
of sepsis in the UK. There are many caveats to the estimates that have been developed but
one of the important outputs from this work has been the identification of gaps in evidence
and data and recommendations about how these gaps can be potentially filled.
2. METHODS
The study adopted a systematic but pragmatic approach to the work, drawing on the best
available evidence. This was derived from two sources:
A burden of illness literature review designed to identify published academic
literature on the costs of sepsis;
Engagement with key opinion leaders (KOLs) to sense check the approach to
costing and provide signposts to other evidence, including any unpublished
evidence.
ii
The literature review sought to find evidence on both direct and indirect costs of sepsis.
Direct costs included hospital costs of care and ongoing care in the community following
discharge, as well as any long-term costs associated with complications and disability
caused by sepsis. Indirect costs included loss of productivity as a result of sepsis and the
costs of litigation from claims against the health service brought by people with sepsis.
The development of the cost model was dictated by the evidence and data found from the
literature reviews, along with any evidence and data that could be added to by the KOLs,
including any assumptions or estimates.
It was originally intended to consider the different populations with sepsis (neonates,
children, adults, elderly), as well as different types of sepsis (sepsis, severe sepsis, septic
shock) and the extent to which evidence and data were applicable across populations and
sepsis type. We found that there was simply not enough evidence to be able to estimate the
incidence of different types of sepsis in the different populations.
The costing framework considered the direct costs associated with in-hospital treatment for
sepsis (e.g. costs of ICU treatment and overall length of hospital stay). Where possible,
these costs were broken down by the different populations with sepsis. Results from the
initial burden of illness review were used to populate these costs, along with pragmatic
searches and sources provided by KOLs to cover any data gaps. The costing framework
also considered longer-term costs associated with three separate areas: litigation; lost
lifetime productivity resulting from mortality; treatment costs for different post-sepsis
complications.
3. RESULTS
The estimated costs of sepsis each year in the UK are £7.76 billion, including approximately
£830 million of direct costs. Applying sensitivity analysis to these costs (higher hospital
costs and lower estimate of average age of death from sepsis for adults of working age)
would give an estimated annual cost of more than £10 billion, including more than £1.1
billion of direct costs. Table 1 summarises the estimated costs.
Table 1: Summary of estimated costs of sepsis (using estimated incidence of
1 exp Systemic Inflammatory Response Syndrome/ (116450) 2 (sepsis$ or septic$ or sepses or postsepsis$ or postseptic$).ti,ab,kf. (132800) 3 (pyoh?emi$ or py?emi$).ti,ab,kf. (223) 4 Bacterial Infections/ and bl.fs. (4901) 5 blood-borne pathogens/ (3021) 6 ((blood or bloodstream) adj3 (poison$ or pathogen$)).ti,ab,kf. (2997) 7 (systemic inflammatory response syndrome$ or SIRS).ti,ab,kf. (6738) 8 (bacter?emi$ or bacill?emi$).ti,ab,kf. (29517) 9 Lemierre Syndrome/ (205) 10 (lemierre$ or necrobacillos$).ti,ab,kf. (812) 11 (fusobacterium adj2 necrophorum).ti,ab,kf. (850) 12 exp Neisseria meningitidis/ (9436) 13 (neisseria adj2 meningitid$).ti,ab,kf. (7985) 14 meningococc?emi$.ti,ab,kf. (812) 15 urosepsis$.ti,ab,kf. (1010) 16 (fung?emi$ or candid?emi$ or parasit?emi$ or vir?emi$).ti,ab,kf. (32081) 17 endotox?emi$.ti,ab,kf. (8975) 18 ((bacterial or endotoxi$ or toxi$) adj3 shock$).ti,ab,kf. (10185) 19 toxic forward failure$.ti,ab,kf. (0) 20 Staphylococcal Infections/ and Methicillin-Resistant Staphylococcus aureus/ (7205) 21 (methicillin resistant staphylococcus aureus infection$ or MRSA infection$).ti,ab,kf. (4130) 22 or/1-21 (264843) 23 Economics/ (28596) 24 exp "costs and cost analysis"/ (217017) 25 Economics, Dental/ (1917) 26 exp economics, hospital/ (23030) 27 Economics, Medical/ (9389) 28 Economics, Nursing/ (4000) 29 Economics, Pharmaceutical/ (2804) 30 (economic$ or cost or costs or costly or costing or price or prices or pricing or
pharmacoeconomic$).ti,ab,kf. (654020) 31 (expenditure$ not energy).ti,ab,kf. (25117) 32 value for money.ti,ab,kf. (1372) 33 budget$.ti,ab,kf. (24771) 34 or/23-33 (787687) 35 ((energy or oxygen) adj cost).ti,ab,kf. (3661) 36 (metabolic adj cost).ti,ab,kf. (1211) 37 ((energy or oxygen) adj expenditure).ti,ab,kf. (23003) 38 or/35-37 (26942) 39 34 not 38 (781715) 40 exp Budgets/ (13597) 41 exp models, economic/ (13060) 42 "Value of Life"/ (5942) 43 ec.fs. (399092) 44 Income/ (26755) 45 Remuneration/ (200) 46 "Salaries and Fringe Benefits"/ (15231) 47 exp "Fees and Charges"/ (30222) 48 (expens$ or earning$ or salar$ or wage$1 or pay or pays or paid or paying or payment$1 or
income$1 or remunerat$ or financ$ or money or monetary or fee or fees or charg$).ti,ab,kf. (595152)
49 or/39-48 (1401476) 50 exp Great Britain/ (362414) 51 (national health service* or nhs*).ti,ab,in. (143510) 52 (english not ((published or publication* or translat* or written or language* or speak* or
literature or citation*) adj5 english)).ti,ab. (30429) 53 (gb or "g.b." or britain* or (british* not "british columbia") or uk or "u.k." or united kingdom* or
(england* not "new england") or northern ireland* or northern irish* or scotland* or scottish* or ((wales or "south wales") not "new south wales") or welsh*).ti,ab,jw,in. (1827760)
Appendix A ii
54 (bath or "bath's" or ((birmingham not alabama*) or ("birmingham's" not alabama*) or bradford or "bradford's" or brighton or "brighton's" or bristol or "bristol's" or carlisle* or "carlisle's" or (cambridge not (massachusetts* or boston* or harvard*)) or ("cambridge's" not (massachusetts* or boston* or harvard*)) or (canterbury not zealand*) or ("canterbury's" not zealand*) or chelmsford or "chelmsford's" or chester or "chester's" or chichester or "chichester's" or coventry or "coventry's" or derby or "derby's" or (durham not (carolina* or nc)) or ("durham's" not (carolina* or nc)) or ely or "ely's" or exeter or "exeter's" or gloucester or "gloucester's" or hereford or "hereford's" or hull or "hull's" or lancaster or "lancaster's" or leeds* or leicester or "leicester's" or (lincoln not nebraska*) or ("lincoln's" not nebraska*) or (liverpool not (new south wales* or nsw)) or ("liverpool's" not (new south wales* or nsw)) or ((london not (ontario* or ont or toronto*)) or ("london's" not (ontario* or ont or toronto*)) or manchester or "manchester's" or (newcastle not (new south wales* or nsw)) or ("newcastle's" not (new south wales* or nsw)) or norwich or "norwich's" or nottingham or "nottingham's" or oxford or "oxford's" or peterborough or "peterborough's" or plymouth or "plymouth's" or portsmouth or "portsmouth's" or preston or "preston's" or ripon or "ripon's" or salford or "salford's" or salisbury or "salisbury's" or sheffield or "sheffield's" or southampton or "southampton's" or st albans or stoke or "stoke's" or sunderland or "sunderland's" or truro or "truro's" or wakefield or "wakefield's" or wells or westminster or "westminster's" or winchester or "winchester's" or wolverhampton or "wolverhampton's" or (worcester not (massachusetts* or boston* or harvard*)) or ("worcester's" not (massachusetts* or boston* or harvard*)) or (york not ("new york*" or ny or ontario* or ont or toronto*)) or ("york's" not ("new york*" or ny or ontario* or ont or toronto*))))).ti,ab,in. (1191312)
55 (bangor or "bangor's" or cardiff or "cardiff's" or newport or "newport's" or st asaph or "st asaph's" or st davids or swansea or "swansea's").ti,ab,in. (44313)
56 (aberdeen or "aberdeen's" or dundee or "dundee's" or edinburgh or "edinburgh's" or glasgow or "glasgow's" or inverness or (perth not australia*) or ("perth's" not australia*) or stirling or "stirling's").ti,ab,in. (172310)
57 (armagh or "armagh's" or belfast or "belfast's" or lisburn or "lisburn's" or londonderry or "londonderry's" or derry or "derry's" or newry or "newry's").ti,ab,in. (20379)
58 or/50-57 (2305365) 59 (exp africa/ or exp americas/ or exp antarctic regions/ or exp arctic regions/ or exp asia/ or
exp australia/ or exp oceania/) not (exp great britain/ or europe/) (2656726) 60 58 not 59 (2211953) 61 22 and 49 and 60 (1128) 62 exp animals/ not humans/ (4669484) 63 (news or comment or editorial or letter or case reports).pt. or case report.ti. (3521168) 64 61 not (62 or 63) (969) 65 limit 64 to (english language and yr="2007 -Current") (629) 66 remove duplicates from 65 (545) Key to Ovid symbols and commands $ Unlimited right-hand truncation symbol * Unlimited right-hand truncation symbol $N Limited right-hand truncation - restricts the number of characters following the word to N ? Wildcard symbol wild card character stands for zero or one characters within a word or at
the end of a word ti,ab,kf. Searches are restricted to the Title, Abstract, or Keyword Heading Word fields adjN Retrieves records that contain terms (in any order) within a specified number (N) of words of
each other / Searches are restricted to the Subject Heading field exp The subject heading is exploded pt. Search is restricted to the publication type field or/1-21 Combines sets 1 to 21 using OR
APPENDIX B
Narrative Synthesis of Eligible Studies in the
Burden of Illness Review
Appendix B i
Narrative synthesis of eligible studies
Andersson is a conference abstract reporting the findings of a costing study of septic shock
in 2012-2013 in England, Wales and Northern Ireland. The total cost was reported as
around £293.2 million.
This comprised critical care (£1,044 per day per patient for 7.6 days totalling £175.2 million),
admission to post-unit discharge location (£240 per day per patient for 23.3 days totalling
about £80.9 million), renal support (£285 per day per person for 5.4 days totalling £6.8
million) and advanced respiratory support (£285 per day per patient for 7.7 days totalling
£30.3 million).
Chin is a cost analysis study aiming to determine whether significant bacteraemia is an
appropriate marker for sepsis and to assess how accurately patients with sepsis are coded
and the financial implications where there is miscoding. Of 54 patients studied in June 2015,
50 were retroactively defined as having sepsis, severe sepsis or septic shock which meant
the hospital had an underpayment of £20,779.
Marlow reports 2-year outcomes from a RCT of prophylaxis with granulocyte-macrophage
colony-stimulating factor (GM-CSF) in very preterm small-for-gestational age (SGA) babies
with neonatal sepsis.
Mean hospital health and social care costs (2007-2008) ranged from £50,464 to £56,339.
Mean follow-up care costs (hospital inpatient and outpatient service use, surgeries
performed, investigative tests, medications and community health and social care resource
use) was reported for 0-6 months (range £3,771 to £5,321), 6-12 months (£2,349 to £2,698),
12-18 months (£1,837 to £1,948) and 18-24 months (£1,753 to £1,963).
Mouncey was a cost effectiveness analysis assessing the effectiveness of the 6-hour early
goal-directed therapy (EGDT) resuscitation protocol for patients with early septic shock, in
England. It reports a range of 2012 hospital costs, including summary costs for monitoring
and consumables, blood products, drugs, staff time, emergency department admission,
critical care unit admission, general medical beds and re-admission costs. It also provided
unit costs for numerous items within each of these mostly sourced from NHS reference
costs, PSSRU or the BNF.
Total costs for up to 90 days ranged from £11,424 to £12,414, and mostly comprised of
critical care unit and general medical bed costs, as well as in-hospital, outpatient and
community costs.
Soares was a Health Technology Assessment which conducted a review of cost
effectiveness studies for intravenous immunoglobulin (IVIG) in sepsis (severe sepsis and
septic shock). IVIG cost £54,901 and standard care was £45,593. Cost input parameters
were also reported.
Appendix B ii
Zia Sadique was a cost effectiveness analysis assessing the effectiveness of Drotrecogin
alfa in routine practice for adult patients with severe sepsis and multiple organ systems
failure. Its effectiveness data is from England, Wales and Northern Ireland and it reports a
range of 2010-2011 hospital costs, including for drug, ICU, bed and readmission costs, both
for the intervention and control groups. It also reports data by number of organ systems
failing (‘2’, ‘3 to 5’ or ‘2 to 5’).
Overall, lifetime costs for patients with 2 to 5 organ systems failing were £36,048 for the
intervention group and £18,432 for the control group. ICU costs ranged from £8,806 to
£22,853. Hospital costs ranged from £3,967 to £5,933. ICU readmission costs ranged from
£914 to £2,152. Hospital readmission costs ranged from £1,652 to £2,823.
References Andersson FL, et al. (2015) Costs of septic shock in England, Wales and Northern Ireland in 2012. Value in Health 18(7):A350. Chin YT et al. (2016) Accurate coding in sepsis: clinical significance and financial implications. Journal of Hospital Infection 94(1): 99-102. Marlow N et al. (2013) A randomised trial of granulocyte-macrophage colony-stimulating factor for neonatal sepsis: outcomes at 2 years. Archives of Disease in Childhood - Fetal and Neonatal Edition 98(1): F46-53. Mouncey PR et al. (2015) Protocolised management in sepsis (ProMISe): a multicentre randomised controlled trial of the clinical effectiveness and cost-effectiveness of early, goal-directed, protocolised resuscitation for emerging septic shock. Health Technology Assessment 19(97): 1-150. Soares MO et al. (2012) An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information exercise. Health Technology Assessment 16(7): 1-186. Tiru, B. et al. (2015) The Economic and Humanistic Burden of Severe Sepsis. Pharmacoeconomics. 2015 Sep;33(9):925-37. Zia Sadique M et al. Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice? Critical Care 15(5): R228.
APPENDIX C
Results of Pragmatic Searches
Appendix C i
Incidence
The Sepsis Trust reports incidence of sepsis for 2013/14 as being just under 123,000 for
England. This appears to correspond with Hospital Episode Statistics (HES) data from NHS
Digital that shows a total of 122,822 finished discharge episodes (FDE) for the year. The
data from NHS Digital also provide the rate of growth in incidence of sepsis over the
previous five years. These data could be used to extrapolate incidence of sepsis across the
rest of the UK using population statistics.
The data include many different ICD10 codes for sepsis but these are not differentiated:
A02.1 Salmonella sepsis;
A20.7 Septicaemic plague;
A21.7 Generalized tularaemia;
A22.7 Anthrax sepsis;
A26.7 Erysipelothrix sepsis;
A28.0 Pasteurellosis;
A28.2 Extraintestinal yersiniosis;
A32.7 Listerial sepsis;
A39.2 Acute meningococcaemia;
A39.3 Chronic meningococcaemia;
A39.4 Meningococcaemia, unspecified;
A40.- Streptococcal sepsis;
A41.- Other sepsis;
A42.7 Actinomycotic sepsis;
B37.7 Candidal sepsis;
O85.X Puerperal sepsis;
P36.- Bacterial sepsis of newborn.
There is potential for under-reporting of sepsis in HES data due to poor recording of sepsis
in patient records and miscoding. YHEC will, therefore, vary the rates of estimated sepsis
to demonstrate the impact if the rate of sepsis is higher than reported. We have also
sourced other data on incidence, including papers such as Hall (2011) and Martin (2012).
We will use these papers to calculate an estimate of the incidence of sepsis in the UK
population based on reported rates of sepsis and population data.
Mortality rates are also reported by The Sepsis Trust, derived from a 2015 paper by
NCEPOD, which gives a mortality rate of 30%. Martin (2012) also provides data on mortality
rates. We will need to use these data to estimate the numbers of people with sepsis who die
each year. Depending on whether the data are differentiated we may be able to provide
some granularity to the estimates, i.e. whether there are different rates of incidence and
mortality in different patient populations (neonates, children, adults).
Given the apparent levels of uncertainty in the data and evidence, it will be important to use
a range of incidence and mortality estimates.
Appendix C ii
Longer-term complications
We have found some studies that refer to longer term complications and disability as a result
of sepsis. The Sepsis Trust refer to:
Post-sepsis syndrome (PSS) defined as the "group of long term problems that some
patients who have experienced severe sepsis can suffer during their rehabilitation
period". The website identifies the following potential long term consequences, as
part of PSS: lethargy, muscle weakness, swollen limbs or joint pain, chest pain or
breathlessness, insomnia, hair loss, dry/flaking skin and nails, changes in taste,
vision and limb sensation, poor appetite, post-sepsis syndrome and repeated
infections;
Potential psychological consequences: anxiety or fear, depression, flashbacks,
nightmares, insomnia, post-traumatic stress disorder (PTSD) and poor
concentration or short-term memory loss;
Problems with organs: kidneys, heart, brain, lungs;
A small percentage of people suffer recurring infection: either a mild version of
original sepsis, or infection in different area of the body. Antibiotics are the usual
the treatment.
Iwashyna (2012): Population burden of long-term survivorship after severe sepsis in older
Americans is a US study of adults age 65+. Around three quarters had functional disability
and around one-sixth had moderate to severe cognitive impairment. No costs were applied.
Boer (2008): Factors associated with post-traumatic stress symptoms in a prospective cohort
of patients after abdominal sepsis: a nomogram. Dutch study of survivors of abdominal
sepsis (for at least 12 months). 28% of patients have moderate PTSD symptom scores and
10% have high scores.
Lopes (2010): Research article Long-term risk of mortality after acute kidney injury in
patients with sepsis: a contemporary analysis. Portuguese study of 454 patients, excluding
renal transplant and chronic kidney disease patients.
Prescott (2016): Late mortality after sepsis: propensity matched cohort study. US study of
mortality after sepsis (i.e. after discharge) - absolute increase in late mortality compared to:
adults not in hospital (22.1%), patients admitted with non-sepsis infection (10.4%), and
patients admitted with sterile inflammatory conditions (16.2%). Mortality remained higher for
at least 2 years relative to adults not in hospital.
Davydow (2012): Depressive symptoms in spouses of older patients with severe sepsis. US
study showing the prevalence of substantial depressive symptoms in wives and husbands of
patients with severe sepsis increased at the time of severe sepsis. The increase in
depression was not explained by bereavement.
Appendix C iii
Indirect costs
We have found one review that refers to indirect costs and a number of other studies that
may also be useful.
Tiru, B., et al. (2015). "The Economic and Humanistic Burden of Severe Sepsis." This was a
review of the burden of severe sepsis, including costs. It reported initial inpatient costs
represent only 30% of the total cost and are related to severity and length of stay, whereas
lost productivity and other indirect medical costs following hospitalization account for the
majority of the economic burden of sepsis. Indirect costs were broken down by: productivity
loss (absenteeism, mortality and early retirement) and healthcare expenditure (after hospital
discharge). The paper cites two studies, one German and one Swiss and then extrapolates
these to estimate a USA cost.
On healthcare expenditure the paper reported that most costs occur after hospital discharge
and that these mostly are accounted for by subsequent admissions. Survivors of severe
sepsis spent nine more days in a health care facility in the following year, compared with
survivors of non-sepsis hospitalisations. Only 20% of severe sepsis survivors were not
hospitalised in the following year.
Chalupka, A. N. and D. Talmor (2012). "The economics of sepsis." The study is not
available freely but its abstract says that it reviews costs of sepsis and its management in
the US, including "indirect costs of the burden of illness imposed by sepsis".
Schmid A, et al. (2004). “Burden of illness imposed by severe sepsis in Switzerland.” This
is the same Swiss study referenced by Tiru.
Burchardi and Schneider (2004). “Economic aspects of severe sepsis: a review of intensive
care unit costs, cost of illness and cost effectiveness of therapy.” This paper is also not
freely available, but it seconds the estimate in the Tiru paper in the abstract, stating that
direct costs make up only 20-30% of the total cost of illness from severe sepsis, with the
biggest contributor being lost productivity due to early mortality.
Other costs
We have found no specific evidence on the costs of litigation in relation to sepsis.
In relation to sepsis in neonates, we have found a number of potentially useful papers.
Wolfler (2008). “Incidence of and mortality due to sepsis, severe sepsis and septic shock in
Italian Pediatric Intensive Care Units: a prospective national survey”. Italian study based on
children in ICU, which is stratified by sepsis, severe sepsis and septic shock. Of 320
children with sepsis-related diagnosis, 216 were allocated to sepsis, 45 to severe and 59 to
septic shock. It also provides mortality data by each group.
Appendix C iv
Hartman (2013). “Trends in the Epidemiology of Pediatric Severe Sepsis”. The full text was
not available, but the abstract gives a paediatric rate of sepsis for USA as 0.89 cases per
1,000 population in 2005. Between 1995 and 2005, severe sepsis in newborns doubled
from 4.5 to 9.7 cases per 1,000 births. In non-newborn infants there are 2.25 cases per
1,000, and the rate is 0.23-0.52 per 1,000 in children 1-19 years of age.
SPROUT Study, Weiss (2015). “Global Epidemiology of Pediatric Severe Sepsis: The
Sepsis Prevalence, Outcomes, and Therapies Study”. This is a large multinational study
showing the prevalence of severe sepsis in paediatric ICU is 8.2%. Mortality was 25% and
did not differ by age.
References Boer KR et al. (2008): Factors associated with post-traumatic stress symptoms in a prospective cohort of patients after abdominal sepsis: a nomogram. Intensive Care Med. 2008 Apr; 34(4): 664–674. Burchardi H and Schneider H (2004) Economic aspects of severe sepsis: a review of intensive care unit costs, cost of illness and cost effectiveness of therapy. Pharmacoeconomics. 2004;22(12):793-813. Chalupka, AN and Talmor D (2012) The economics of sepsis. Crit Care Clin. 2012 Jan;28(1):57-76. Davydow DS et al. (2012) Depressive symptoms in spouses of older patients with severe sepsis. Crit Care Med. 2012 Aug;40(8):2335-41. Hall MJ et al. (2011) Inpatient Care for Septicemia or Sepsis: A Challenge for Patients and Hospitals. NCHS Data Brief No. 62 June 2011. Hartman ME et al. (2013) Trends in the Epidemiology of Pediatric Severe Sepsis. Pediatr Crit Care Med. 2013 Sep;14(7):686-93. Iwashina T et al. (2012) Population Burden of Long-Term Survivorship After Severe Sepsis in Older Americans. JAGS 60:1070–1077. Lopes JM et al. (2010) Long-term risk of mortality after acute kidney injury in patients with sepsis: a contemporary analysis. BMC Nephrology 2010 11:9. Martin G. (2012) Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes. Expert Rev Anti Infect Ther. 2012 June ; 10(6): 701–706 Prescott HC et al. (2016) Late mortality after sepsis: propensity matched cohort study. BMJ 2016; 353. Schmid A et al. (2004) Burden of illness imposed by severe sepsis in Switzerland. University of Zurich. Zurich Open Repository and Archive. Weiss SL et al. (2015) Global Epidemiology of Pediatric Severe Sepsis: The Sepsis Prevalence, Outcomes, and Therapies Study. Am J Respir Crit Care Med. 2015 May 15;191(10):1147-57.
Appendix C v
Wolfler A et al. (2008) Incidence of and mortality due to sepsis, severe sepsis and septic shock in Italian Pediatric Intensive Care Units: a prospective national survey. Intensive Care Med. 2008 Sep;34(9):1690-7.